13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2021-12-31, filed 2022-02-14, with 23 holding rows worth $217,913,000.
- Accession
- 0001567619-22-003693
- Filer
- CIK 1440771
- Filed
- 2022-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2021
A holdings report, 23 entries on the cover page, a total value of $217,913,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $217,913,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMRYT PHARMA LTD - SPNR ADR | 03217L106 | COMMON EQUITY | 6,069,775 | $65,554,000 | thousands by filing date | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 8,800,358 | $21,825,000 | thousands by filing date | |
| XERIS BIOPHARMA HOLDINGS INC | 98422E103 | COM | 5,656,373 | $16,573,000 | thousands by filing date | |
| ADMA BIOLOGICS INC | 000899104 | COM | 9,911,577 | $13,975,000 | thousands by filing date | |
| OVID THERAPEUTICS INC | 690469101 | COMMON STOCK | 4,006,185 | $12,860,000 | thousands by filing date | |
| EVOLUS INC | 30052C107 | COM | 1,863,096 | $12,129,000 | thousands by filing date | |
| CONFORMIS INC | 20717E101 | COM | 14,768,823 | $11,245,000 | thousands by filing date | |
| EXAGEN INC | 30068X103 | COM | 858,567 | $9,985,000 | thousands by filing date | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 1,151,163 | $9,704,000 | thousands by filing date | |
| ANTARES PHARMA INC | 036642106 | COM | 2,297,360 | $8,202,000 | thousands by filing date | |
| OPTINOSE INC | 68404V100 | COM | 3,844,230 | $6,228,000 | thousands by filing date | |
| DIAMEDICA THERAPEUTICS INC | 25253X207 | COMMON STOCK | 1,194,670 | $4,456,000 | thousands by filing date | |
| ATYR PHARMA INC | 002120202 | COM NEW | 525,531 | $3,926,000 | thousands by filing date | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 808,405 | $3,864,000 | thousands by filing date | |
| CELCUITY INC | 15102K100 | COM | 239,433 | $3,158,000 | thousands by filing date | |
| CIDARA THERAPEUTICS INC COM NEW | 171757107 | Stock | 2,311,530 | $2,936,000 | thousands by filing date | |
| SYNLOGIC INC | 87166L100 | COM | 1,064,135 | $2,575,000 | thousands by filing date | |
| AVALO THERAPEUTICS INC | 05338F108 | CMN | 1,510,095 | $2,567,000 | thousands by filing date | |
| ANI PHARMACEUTICALS INC | 00182C103 | COM | 52,290 | $2,410,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 300,000 | $1,014,000 | thousands by filing date | |
| NEUROONE MED TECHNOLOGIES CORP COM | 64130M209 | Stock | 498,354 | $967,000 | thousands by filing date | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 46,026 | $960,000 | thousands by filing date | |
| ALDEYRA THERAPEUTICS INC | 01438T106 | COM | 200,000 | $800,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001567619-22-003693 | this filing | 2022-02-14 | acceptance time not in the bulk data set |